Neuropsychiatric disease and treatment
January 1, 2024
Nadav Liam Modlin, Michael Creed, Maria Sarang et al.
18 citations
Patients with post-traumatic stress disorder (PTSD) often find standard psychotherapies burdensome and drop out. Psychedelic therapy (PT) shows promise for difficult-to-treat conditions, but trials of classical psychedelics for PTSD are lacking. This systematic review of 40 qualitative studies (26 on evidence-based psychotherapies for PTSD, 14 on PT for various conditions) found overlapping themes: both therapies involve key mechanisms of change, require psychological safety and readiness, and can burden patients. In PT, indirect trauma processing and reorganization of self-narratives emerged as unique themes. Trauma-informed care may improve safety and acceptability of PT research.
Psychedelic Medicine
November 26, 2024
Nadav Liam Modlin, Tyler McPhee, Nira Zazon et al.
5 citations
People who use psychedelics and attend integration groups report that these groups provide essential community support and help process psychedelic experiences, but also face challenges such as managing group dynamics and ensuring facilitators are adequately trained. Three main themes emerged: reasons for attending, utility of the groups, and adverse factors affecting experience. While integration groups can reduce some risks of unregulated psychedelic use, research is needed to develop standardized protocols and facilitator training to improve their safety and effectiveness.
Psychiatry and Clinical Psychopharmacology
August 14, 2025
Nadav Liam Modlin, Jessica L. Maples‐keller, Maria Sarang et al.
Among 873 people who reported trauma symptoms or a PTSD/CPTSD diagnosis, 94.8% had experienced psychological trauma and 73.4% had a formal diagnosis. Many had tried multiple medications and psychotherapies but were highly dissatisfied. Significant numbers used marijuana, psychedelics, or MDMA on their own to manage symptoms, with few physical or psychological complications. After learning about MDMA and psilocybin therapies, willingness to try them was high (0.81 and 0.83, respectively). Women and heterosexual individuals showed lower willingness, while younger and more educated respondents were more willing. The findings point to a need for further clinical research and public education about risks and harm reduction.